DoubleTwist Licenses Prophecy Database to GPC Biotech | GenomeWeb

NEW YORK, Oct. 16 – DoubleTwist has licensed its Prophecy database and tools suite to GPC Biotech, the company said on Tuesday.

Financial terms of the agreement were not disclosed.

"DoubleTwist's Prophecy suite gives us comprehensive access to annotated public genome data and effective tools for their use,” Greg Hamm, vice president for bioinformatics at GPC Biotech said in a statement. “We are looking forward to mining this valuable data set.”

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.